SC
IMCR icon

Stempoint Capital’s Immunocore IMCR Stock Holding History

Stempoint Capital’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,543
Closed -$1.92M – 95
2026
Q1 		$1.92M Buy
+63,543
New +$2.06M 0.37% 56
2024
Q3 		– Sell
-339,351
Closed -$11.5M – 60
2024
Q2 		$11.5M Buy
+339,351
New +$17.3M 3.38% 8

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Stempoint Capital's IMCR Position: Q2 2026 in Review

Stempoint Capital sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 63,543 shares — an estimated $1.92M sold.

Stempoint Capital first reported a position in IMCR in Q2 2024 and held it in 2 quarters. The position peaked at $11.5M in Q2 2024. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Stempoint Capital reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 63,543 Immunocore shares in Q2 2026, an estimated $1.92M.
  • Stempoint Capital first reported a position in Immunocore in Q2 2024 and held it in 2 quarters.
  • Stempoint Capital's Immunocore position peaked at $11.5M in Q2 2024.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.